BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 11563569)

  • 1. New tests for cervical cancer screening.
    Nuovo J; Melnikow J; Howell LP
    Am Fam Physician; 2001 Sep; 64(5):780-6. PubMed ID: 11563569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
    BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is a Pap smear enough?
    Heley S
    Aust Fam Physician; 2001 Jun; 30(6):535-8. PubMed ID: 11458579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical cancer screening in the early post vaccine era.
    Waxman AG
    Obstet Gynecol Clin North Am; 2008 Dec; 35(4):537-48; vii. PubMed ID: 19061815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid-based cytology for cervical cancer screening.
    Bentz JS
    Expert Rev Mol Diagn; 2005 Nov; 5(6):857-71. PubMed ID: 16255628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ThinPrep Papanicolaou testing to reduce false-negative cervical cytology.
    Linder J; Zahniser D
    Arch Pathol Lab Med; 1998 Feb; 122(2):139-44. PubMed ID: 9499356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus testing for primary cervical cancer screening.
    Grce M; Davies P
    Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
    Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
    Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?
    Wright TC
    Clin Obstet Gynecol; 2007 Jun; 50(2):313-23. PubMed ID: 17513921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New technologies in gynecologic cytology.
    Bishop JW; Marshall CJ; Bentz JS
    J Reprod Med; 2000 Sep; 45(9):701-19. PubMed ID: 11027079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the cytology laboratory: specimen processing through diagnosis.
    Joste N
    Obstet Gynecol Clin North Am; 2008 Dec; 35(4):549-63; viii. PubMed ID: 19061816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in cervical screening technology.
    Stoler MH
    Mod Pathol; 2000 Mar; 13(3):275-84. PubMed ID: 10757338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Integrating HPV testing for primary screening?].
    Riethmuller D; Ramanah R; Pretet JL; Mougin C
    J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S139-51. PubMed ID: 18191912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Can human papillomavirus testing and vaccination prevent cervical cancer?].
    Lie AK; Bjørge T; Helland A; Hagen B; Skjeldestad FE; Hagmar B; Thoresen S
    Tidsskr Nor Laegeforen; 2001 Oct; 121(25):2947-51. PubMed ID: 11715778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
    Schindeler S; Morrell S; Zuo Y; Baker D
    J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical cancer, Pap smear and HPV testing: an update of the role of organized Pap smear screening and HPV testing.
    Sigurdsson K
    Acta Obstet Gynecol Scand; 1999 Jul; 78(6):467-77. PubMed ID: 10376855
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
    Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
    J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
    Zhao C; Austin RM
    Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
    Cibas ES; Hong X; Crum CP; Feldman S
    Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
    Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
    J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.